Compliance with RSV prophylaxis: Global physicians’ perspectives
Kari S Anderson, Victoria M Mullally, Linda M Fredrick, Andrew L CampbellAbbott Laboratories, Abbott Park, IL, USAAbstract: Respiratory syncytial virus (RSV) is a significant cause of morbidity in high-risk infants. Palivizumab is proven to prevent serious RSV disease, but compliance with prophylaxi...
Main Authors: | Kari S Anderson, Victoria M Mullally, Linda M Fredrick, Andrew L Campbell |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-07-01
|
Series: | Patient Preference and Adherence |
Online Access: | http://www.dovepress.com/compliance-with-rsv-prophylaxis-global-physiciansrsquo-perspectives-a3350 |
Similar Items
-
Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina
by: Suada Heljic, et al.
Published: (2016-02-01) -
Factors affecting therapeutic compliance: A review from the patient’s perspective
by: Jing Jin, et al.
Published: (2008-03-01) -
Global molecular diversity of RSV – the “INFORM RSV” study
by: Annefleur C. Langedijk, et al.
Published: (2020-06-01) -
Bendamustine in the treatment of non-Hodgkin’s lymphomas
by: Fredrick Hagemeister, et al.
Published: (2009-12-01) -
Physicians’ perceptions, expectations, and experience with pharmacists at Hamad Medical Corporation in Qatar
by: Zaidan M, et al.
Published: (2011-04-01)